ALINT.PA IntegraGen SA slides on EURONEXT 11 Feb 2026: assess liquidity risk

ALINT.PA stock is trading at €0.19 intraday on EURONEXT after hitting a day low of €0.15 with volume of 166,168 shares. The intraday move places IntegraGen SA (ALINT.PA) among top losers on 11 Feb 2026 in Europe. Traders cite thin market depth, a 50-day average near €0.15, and weak fundamentals as pressure points for the Healthcare biotechnology name.

ALINT.PA stock intraday move and liquidity

IntegraGen SA (ALINT.PA) opened at €0.15 and traded between €0.15 and €0.21 today on EURONEXT. The stock shows a relative volume of 1.50, indicating volume nearly 150% of normal and heavier selling pressure.

High intraday volume and a small market cap of €1,139,672.00 raise liquidity risk for larger orders. Shares outstanding are 6,606,796 which magnifies price swings when daily volume spikes.

Price drivers and recent news

There is no company-specific press release driving today’s drop; market participants reference sector comparisons and listed-company flows. Benchmark and listing updates from Euronext pages influence small-cap activity source.

Third-party comparisons also appear in regional analyst tools and peer screens, which can amplify moves in low-liquidity biotech names like IntegraGen SA (ALINT.PA) source.

Financials and valuation for ALINT.PA stock

IntegraGen reports trailing EPS of -0.04 and a price-to-earnings metric shown as -4.31, reflecting losses. Price-to-sales is low at 0.17, but book value per share sits at 0.05, giving a price-to-book near 3.37 and limited tangible equity cushion.

The company shows a current ratio of 1.19 and debt-to-equity of 1.23, indicating leverage relative to peers. These ratios, combined with negative operating cash flow per share -0.10, explain limited near-term upside in valuation models.

Technicals and trading signals for ALINT.PA stock

Momentum indicators are muted: RSI is 43.73 and ADX is 15.03, signalling no clear trend. The 50-day average is €0.15 and the 200-day average is €0.27, placing the current price below longer-term trend lines.

Short-term charts show Bollinger middle at €0.14 and ATR at €0.01, pointing to tight intraday ranges but big percentage moves. Traders should note a wide year range from €0.12 to €0.73, which underscores volatility.

Meyka AI grade and model forecast

Meyka AI rates ALINT.PA with a score out of 100. Meyka AI rates ALINT.PA with a score of 61.56 (Grade B) and suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly level of €0.09, driven by current cash, revenue per share, and low liquidity. Forecasts are model-based projections and not guarantees. See the Meyka stock page for live updates: Meyka ALINT.PA.

Risks, sector context and price targets

Key risks: limited liquidity, negative EPS, and leverage. Sector peers in Healthcare show average ROE near 5.86%, making IntegraGen’s negative returns stand out. IntegraGen is a small biotech provider of genomic services and faces competitive pressure from larger sequencing players.

Realistic near-term price targets: conservative recovery to €0.30 (implied upside +57.89%). A recovery scenario to €0.60 would imply +215.79%, but both targets depend on business updates and volume normalization.

Final Thoughts

IntegraGen SA (ALINT.PA) ranks among intraday top losers on EURONEXT on 11 Feb 2026, trading at €0.19 with heightened volume of 166,168 shares. Technicals and valuation both point to caution: RSI 43.73, 50-day average €0.15, EPS -0.04, and price-to-book 3.37. Liquidity is the immediate issue; the market cap is €1,139,672.00, which can magnify price moves on limited order flow. Meyka AI’s forecast model projects €0.09 monthly for ALINT.PA stock, implying an expected downside of -52.63% versus the current price. Our Meyka grade of 61.56 (B, HOLD) balances small-cap risk against operational assets and niche genomic services. Investors focused on ALINT.PA stock should prioritise confirmation of trading depth and await company updates or earnings before adding exposure. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.